We write about science every day, why isn’t it getting through to the public consciousness? Source: BioSpace

Barely a week after announcing it was moving into a new corporate headquarters, Sangamo announced it has dosed the first patient in its Phase I/II gene therapy trial. Source: BioSpace

The $49M in Series A funding will be used to develop the company's enzyme replacement therapies for two rare diseases affecting infants and children and push the treatments into the…

It's not always easy to see when a company is a "disruptor," which is to say, that it causes a paradigm shift in how an industry operates. Source: BioSpace

The cash will fund a randomized Phase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen-DQ2.5 (HLA-DQ2.5) immune recognition gene. Source: BioSpace

The new space is located just a few miles from Kendall Square that has become the hub of the Boston biotech industry. Source: BioSpace

Investors love to speculate on M&A, and one of the hottest topics of speculation recently has been whether someone will buy BMS. Source: BioSpace

Two days after Mylan CEO Heather Bresch said she sees a "strong finish" for the company through the rest of 2017, the company has reportedly let between 200 and 300…

Beleaguered Avinger, is slashing more jobs. Source: BioSpace

Novartis is not resting on the laurels of having the first-ever-approval for a CAR-T cancer drug, Kymriah. Source: BioSpace